8-K: TriSalus Life Sciences Announces CFO Transition, Appoints David Patience Amidst Leadership Reshuffle

TriSalus Life Sciences, Inc. has announced the resignation of its Chief Financial Officer, James Young, effective May 30, 2025, and the appointment of David B. Patience as his successor, effective July 1, 2025.

Summary

• James Young resigned as Chief Financial Officer of TriSalus Life Sciences, Inc. for personal reasons, effective May 30, 2025.
• Pursuant to an Agreement and Release, Mr. Young will receive six months of his annual salary as severance, paid in equal installments from June 1, 2025, to November 30, 2025.
• Mr. Young's equity subject to vesting will continue to vest until May 31, 2026.
• David B. Patience has been appointed as the new Chief Financial Officer, with his employment commencing on July 1, 2025.
• During the transition period from May 30, 2025, to July 1, 2025, Dan Giordano, Vice President of Finance, will serve as acting CFO.
• Mr. Patience's compensation package includes an annual base salary of $450,000 and a sign-on bonus of $159,000.
• He will be eligible for an annual bonus of up to 50% of his base salary, contingent on achieving financial goals and milestones.
• The Company will recommend granting Mr. Patience stock options equal to 1% of the Company's issued and outstanding common stock, and he will be eligible for a performance equity grant in the first quarter of 2026.
• Mr. Patience previously served as CFO of Accelerate Diagnostics since 2023 and has experience in investment banking and financial research.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a CFO departure can be a concern, the immediate and seemingly well-qualified replacement, coupled with a clear transition plan and the new CFO's capital markets experience, mitigates potential negative impact. The company's ongoing clinical trial progress also contributes positively, despite inherent industry risks.

Positives

• The appointment of David B. Patience, an accomplished healthcare CFO with deep experience in the life sciences sector and capital markets, is expected to be invaluable for TriSalus's next phase of growth.
• The company has ensured a smooth leadership transition with an interim CFO, Dan Giordano, and Mr. Young remaining available for support.

Negatives

• The departure of an experienced CFO, James Young, could introduce a period of adjustment for the company's financial operations.
• The severance package for the departing CFO, including six months of salary and continued equity vesting for a year, represents a financial outlay.

Risks

• Risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates.
• Future clinical results may not be consistent with patient data generated during the Company's clinical trials.
• The cost and timing of all development activities and clinical trials may exceed expectations.
• Unexpected safety and efficacy data could be observed during clinical studies.
• Risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations to avoid an event of default.
• The risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations.
• The risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• The risk that the Company will not become profitable on its expected timeline, if at all.
• Reported financial results may differ from estimates provided.
• Changes in expected or existing competition or market conditions.
• Changes in the regulatory environment.
• Unexpected litigation or other disputes.
• Unexpected expensed costs.

Future Outlook

TriSalus Life Sciences anticipates continued progress in its oncology focus, leveraging its proprietary Pressure-Enabled Drug Delivery (PEDD) technology and investigational immunotherapeutic, nelitolimod. The company is in the final stages of data completion for several Phase 1 clinical trials and plans to explore partnership opportunities for development. The company aims to transform outcomes for patients with solid tumors by improving drug delivery and addressing the immunosuppressive tumor environment.

Management Comments

• "We are thrilled to welcome David to our leadership team. Davids strong expertise in capital markets and proven track record of financial leadership and operational execution will be invaluable and play a crucial role as we drive our next phase of growth." Mary Szela, President and CEO of TriSalus Life Sciences.
• "On behalf of our leadership team, I also thank Jim Young for his service and contributions. We wish him the best in his future endeavors." Mary Szela, President and CEO of TriSalus Life Sciences.

Industry Context

This CFO transition occurs within the dynamic and capital-intensive life sciences and oncology sectors. Companies in this space frequently undergo leadership changes to align with strategic growth phases, particularly as they advance clinical trials and explore commercialization or partnership opportunities. The appointment of a CFO with strong capital markets experience, like David Patience, suggests TriSalus is positioning itself for potential future financing activities or strategic transactions, which is a common trend for biotech firms moving from clinical development to commercialization.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or financial results to assess against global benchmarks. The focus is on a management change and associated compensation.

Management Changes

Stakeholder Impact

• **Shareholders:** The transition of a key executive like the CFO can impact investor confidence. The appointment of an experienced replacement aims to reassure shareholders about financial leadership and strategic direction. The potential for future capital raises, as indicated by risks, could lead to dilution.
• **Employees:** The departure of a senior executive and the arrival of a new one can affect internal dynamics and morale. The interim appointment ensures continuity.
• **Customers/Partners:** Unlikely to have direct immediate impact, but stable financial leadership is crucial for long-term business relationships and strategic partnerships.

Next Steps

• David B. Patience's employment as Chief Financial Officer is expected to start on July 1, 2025.
• Dan Giordano will serve as acting Chief Financial Officer during the transition period until July 1, 2025.
• The Company will recommend a stock option grant for Mr. Patience equal to 1% of issued and outstanding common stock following the start of his employment.
• Mr. Patience will be eligible for a performance equity grant in the first quarter of 2026.
• The Company is in the final stages of data completion for a number of Phase 1 clinical trials.
• The Company will begin exploring partnership opportunities for development of its investigational immunotherapeutic, nelitolimod.

Key Dates

Recommendation

Keywords

TriSalus Life Sciences, TLSI, CFO appointment, Chief Financial Officer, David Patience, James Young, executive change, SEC filing, 8-K, oncology, medical technology, PEDD technology, nelitolimod, life sciences, corporate governance